Centivax Antibody Effective in Reducing COVID-19 Lung Damage, Virus Levels and Symptoms as Both Therapeutic and Preventative in Healthy and Immunocompromised Hamsters; Confirmed by Multiple National Laboratories

Excerpt from the press release:

“SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today that their antibody therapeutic protects hamsters from SARS-CoV-2, the COVID-19-causing coronavirus. Confirmed simultaneously at two independent national laboratories, these results provide critical support for the antibody to move to clinical studies to protect and treat human patients. At the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in the Department of Defense (DoD), the Centivax lead antibody was administered to hamsters preventatively to protect against future exposures. The researchers found that the antibody protected the hamsters from COVID-19 symptoms and radically reduced the amount of the pathogenic virus in hamster lungs, even in immunocompromised hamsters. At the University of Texas Medical Branch/Galveston National Laboratory (UTMB/GNL) the Centivax lead antibody was administered as a therapeutic to previously infected hamsters: within 48 hours, the hamsters had a 97% reduction of virus in the lungs and significantly reduced lung damage.”

Click the button below to read the article:

Continue Reading The Article